Literature DB >> 18677022

Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa.

Elvin H Geng, Nneka Emenyonu, Mwebesa Bosco Bwana, David V Glidden, Jeffrey N Martin.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18677022      PMCID： PMC3711416          DOI： 10.1001/jama.300.5.506

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring.

Authors:  C E Frangakis; D B Rubin
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

2.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

Authors:  Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

Review 3.  Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox; Christopher J Gill
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069
  3 in total
  127 in total

1.  A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa.

Authors:  Elvin H Geng; David V Glidden; David R Bangsberg; Mwebesa Bosco Bwana; Nicholas Musinguzi; Denis Nash; John Z Metcalfe; Constantin T Yiannoutsos; Jeffrey N Martin; Maya L Petersen
Journal:  Am J Epidemiol       Date:  2012-02-03       Impact factor: 4.897

2.  Outcomes of antiretroviral treatment programs in rural Southern Africa.

Authors:  Gilles Wandeler; Olivia Keiser; Karolin Pfeiffer; Sabrina Pestilli; Christiane Fritz; Niklaus D Labhardt; Franzisco Mbofana; Robert Mudyiradima; Jan Emmel; Matthias Egger; Jochen Ehmer
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

3.  Prevalent tuberculosis and mortality among HAART initiators.

Authors:  Daniel Westreich; Matthew P Fox; Annelies Van Rie; Mhairi Maskew
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

4.  A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the Caribbean.

Authors:  Mark J Giganti; Paula M Luz; Yanink Caro-Vega; Carina Cesar; Denis Padgett; Serena Koenig; Juan Echevarria; Catherine C McGowan; Bryan E Shepherd
Journal:  AIDS Res Hum Retroviruses       Date:  2015-03-06       Impact factor: 2.205

5.  Choosing profile double-sampling designs for survival estimation with application to President's Emergency Plan for AIDS Relief evaluation.

Authors:  Ming-Wen An; Constantine E Frangakis; Constantin T Yiannoutsos
Journal:  Stat Med       Date:  2014-01-10       Impact factor: 2.373

6.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa.

Authors:  Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian
Journal:  Int J Epidemiol       Date:  2011-05-18       Impact factor: 7.196

Review 7.  The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.

Authors:  Mark J Siedner; Mwebesa B Bwana; Mahomed-Yunus S Moosa; Michelle Paul; Selvan Pillay; Suzanne McCluskey; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi
Journal:  HIV Clin Trials       Date:  2017-07-18

Review 8.  Study design issues in evaluating immune biomarkers.

Authors:  Ronald J Bosch; Xinyan Zhang; Netanya G Sandler
Journal:  Curr Opin HIV AIDS       Date:  2013-03       Impact factor: 4.283

9.  Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.

Authors:  Benjamin H Chi; Albert Mwango; Mark Giganti; Lloyd B Mulenga; Bushimbwa Tambatamba-Chapula; Stewart E Reid; Carolyn Bolton-Moore; Namwinga Chintu; Priscilla L Mulenga; Elizabeth M Stringer; Robert Sheneberger; Peter Mwaba; Jeffrey S A Stringer
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

10.  Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda.

Authors:  Elvin H Geng; Mwebesa B Bwana; Winnie Muyindike; David V Glidden; David R Bangsberg; Torsten B Neilands; Ingrid Bernheimer; Nicolas Musinguzi; Constantin T Yiannoutsos; Jeffrey N Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.